Abstract
The present study aimed at development of capsular dosage form of surface-adsorbed nanoemulsion (NE) of olmesartan medoxomil (OLM) so as to overcome the limitations associated with handling of liquid NEs without affecting their pharmaceutical efficacy. Selection of oil, surfactant, and cosurfactant for construction of pseudoternary phase diagrams was made on the basis of solubility of drug in these excipients. Rationally selected NE formulations were evaluated for percentage transmittance, viscosity, refractive index, globule size, zeta potential, and polydispersity index (PDI). Formulation (F3) comprising of Capmul MCM® (10% v/v), Tween 80® (11.25% v/v), polyethylene glycol 400 (3.75% v/v), and double-distilled water (75% v/v) displayed highest percentage cumulative drug release (%CDR; 96.69 ± 1.841), least globule size (17.51 ± 5.87 nm), low PDI (0.203 ± 0.032), high zeta potential (−58.93 ± 0.98 mV), and hence was selected as the optimized formulation. F3 was adsorbed over colloidal silicon dioxide (2 ml/400 mg) to produce free-flowing solid surface-adsorbed NE that presented a ready-to-fill capsule composition. Conversion of NE to surface-adsorbed NE and its reconstitution to NE did not affect the in vitro release profile of OLM as the similarity factor with respect to NE was found to be 66% and 73% respectively. The %CDR after 12 h for optimized NE, surface-adsorbed NE, and reconstituted NE was found to be 96.69 ± 0.54, 96.07 ± 1.76, and 94.78 ± 1.57, respectively (p > 0.05). The present study established capsulated surface-adsorbed NE as a viable delivery system with the potential to overcome the handling limitations of NE.
Similar content being viewed by others
References
Murakamia T, Konnoa H, Fukutsua N, Onoderaa M, Kawasakia T, Kusub F. Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques. J Pharmaceut Biomed Anal. 2008;47:553–9.
Park JH, Chang JS, El-Gamal MI, Choi WK, Lee WS, Chung HJ, et al. Novel amides and esters prodrugs of olmesartan: synthesis, bioconversion, and pharmacokinetic evaluation. Bioorg Med Chem Lett. 2010;20:5895–9.
Klaus O, Stumpe MD. Olmesartan compared with other angiotensin II receptor antagonists: head to head trial. Clin Ther. 2004;26:A33–7.
Wehling M. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control? Clin Ther. 2004;26:A21–7.
Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T. Oatp1b1, Oatp1b3 and Mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II Blocker. Drug Metabol Dispos. 2006;34:862–9.
Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, et al. Identification of the hepatic efflux transporters of organic anions using doubletransfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistanceassociated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast. J Pharmacol Exp Ther. 2005;314:1059–67.
Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery system. Adv Drug Deliv Rev. 2000;45:89–121.
Qian C, McClements DJ. Formation of nanoemulsions stabilized by model food-grade emulsifiers using high-pressure homogenization: factors affecting particle size. Food Hydrocolloids. 2011;25:1000–8.
Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water soluble, drugs. Drug Discov Today. 2011;16:354–60.
Shono Y, Nishihara H, Matsuda Y, Furukawa S, Okada N, Fujita T, et al. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci. 2004;93:877–85.
Lee BS, Kang MJ, Choi WS, Choi YB, Kim HS, Lee SK, et al. Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability. Arch Pharm Res. 2009;132:1629–35.
Bali V, Ali M, Ali J. Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment. Int J Pharm. 2011;403:46–56.
Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today. 2010;15:958–65.
Vior MCG, Monteagudo E, Dicelio LE, Awruch J. A comparative study of a novel lipophilic phthlocyanine incorporated into NE formulation: photophysics, size, solubility and thermodynamic stability. Dyes Pig. 2011;91:208–14.
Mandawgade SD, Sharma S, Pathak S, Patrawale VB. Development of SMEDDS using natural lipophile: application to artemether delivery. Int J Pharm. 2008;362:179–83.
Date AA, Nagarsenker MS. Design and evaluation of self nanoemulsifying drug delivery system (SNEDDS) for cefpodoxime proxetil. Int J Pharm. 2007;329:166–72.
Patel AR, Vavia PR. Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J. 2007;9:E344–52.
Nazzal S, Khan MA. Controlled release of a self-emulsifying formulation from a tablet dosage form: stability assessment and optimization of some processing parameters. Int J Pharm. 2006;315:110–21.
Sinko PJ. Martin’s pharmacy and pharmaceutical sciences. 5th ed. Woltre Kulwer (India) Pvt Ltd.; 2008.
Laies P, Puchler K, Kirch W. The pharmacokinetics and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens. 2001;19:S21–32.
Shinoda K, Kuneda H. The effect of salt concentration, temperature, and additives on the solvent property of aerosol OT solution. J Colloid Interface Sci. 1987;118:586–9.
Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66:227–43.
Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm. 1998;167:155–64.
Rajpoot P, Bali V, Pathak K. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan. Int J Pharm. 2012;426:219–30.
Constanitinides PP, Scalart JP, Lancaster C, Marcello J, Marks G, Ellens H. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm Res. 1994;11:1385–90.
Gershanik T, Benzeno S, Benita S. Interaction of the self-emulsifying lipid drug delivery system with mucosa of everted rat intestine as a function of surface charge and droplet size. Pharm Res. 1998;15:863–9.
Yoo JH, Shanmugam S, Thapa P, Lee ES, Balakrishnan P, Yoo SK. Novel self-nanoemulsifying drug delivery system for enhanced solubility and dissolution of lutein. Arch Pharm Res. 2010;33:417–26.
Gursoy RN, Benita S. Self-emulsifying drug delivery system (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58:173–82.
Pouton C. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev. 1997;25:47–58.
Row CR, Sheskey PJ, Owe SC. Handbook of pharmaceutical excipients. 5th ed. Royal society of Great Britain; 2006.
Aulton ME. The science of dosage form design. 2nd ed. London: Churchill & Livingstone; 2002.
Gennaro AR. Remington: the science and practice of pharmacy. 20th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.
Acknowledgments
The authors are thankful to Sun Pharmaceutical Industries, Sikkim, India for providing the gift sample of olmesartan medoxomil.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singh, S., Pathak, K. & Bali, V. Product Development Studies on Surface-Adsorbed Nanoemulsion of Olmesartan Medoxomil as a Capsular Dosage Form. AAPS PharmSciTech 13, 1212–1221 (2012). https://doi.org/10.1208/s12249-012-9847-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-012-9847-7